TransThera Sciences completes HK$290 million H-share placement at HK$57.03 each

• TransThera Sciences completed private placement of 5,085,000 new H shares at HK$ 57.03 each on April 21, 2026.
• Gross proceeds totaled about HK$ 290 million; net proceeds were about HK$ 282.2 million.
• Funds earmarked mainly for R&D and clinical development of Tinengotinib, with additional allocation toward manufacturing and commercialization in China.
• Total issued shares rose to 404,082,633 from 398,997,633 following issue of placing shares.
• Placees bought about 1.3% of enlarged share capital; none became substantial shareholder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences (Nanjing) Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260421-12114117), on April 21, 2026, and is solely responsible for the information contained therein.